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BACKGROUND: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer,
but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.
METHODS: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified.
Meta-analysis was performed using a DerSimonian–Laird model. Publication bias was investigated using funnel plots and sources of
heterogeneity were identified using meta-regression analysis.
RESULTS: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a
modest effect on overall survival (pooled HR 1.47, 95% CI 1.33–1.61 for p53; HR 1.65, 95% CI 1.25–2.19 for EGFR and HR 1.67,
95% CI 1.34–2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome.
For EGFR and HER-2/neu, considerable publication bias was present.
CONCLUSIONS: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to
be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more
complete reporting of results of prognostic factor studies.
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Epithelial ovarian cancer is the leading cause of death from
gynaecological cancers in the Western world. This high mortality is
related to the difficulty to detect ovarian cancer at an early stage as
well as the lack of effective therapies for advanced-stage disease
(Cannistra, 2004).
Prognostic factors are defined as phenotypes, which correlate
with the duration of (progression-free) survival (Agarwal and
Kaye, 2005). In ovarian cancer, well-known clinicopathological
prognostic factors in early-stage disease include differentiation
grade and tumour rupture during surgery, whereas in late-stage
disease histiotype, patient age, performance status and residual
tumour after primary surgery are important prognostic factors
(Vergote et al, 2001; Winter et al, 2007). Although these
parameters do reflect biological features of both tumour and
patient, they do not allow adequate prediction of outcome for the
individual patient. The discovery of molecular biological prog-
nostic factors should aid in a more accurate prediction of clinical
outcome and may also reveal novel predictive factors and
therapeutic targets (Oldenhuis et al, 2008).
The most frequently studied putative molecular biological
prognostic factors in ovarian cancer are the tumour suppressor
protein 53 (p53), and the oncogenes epidermal growth factor
receptor (EGFR) and human epidermal growth factor receptor 2
(HER-2/neu). These markers also hold considerable promise as
therapeutic targets. Agents targeting p53, EGFR and HER-2/neu
proteins are currently under investigation in clinical trials (Dinh
et al, 2008). However, evidence regarding their prognostic value
with respect to survival is still inconclusive. Results of systematic
reviews, including one from our institution, showed that these
markers might predict prognosis in ovarian cancer, and also
suggested considerable methodological variability (Crijns et al,
2003; Hall et al, 2004). The identification of these methodological
weaknesses and sources of heterogeneity is important to improve
the quality of future prognostic and predictive factor studies in
ovarian cancer and other tumour types.
The aim of this study was to more precisely estimate the
prognostic value of these markers and to adjust for methodological
variability. We have used statistical methods developed by Parmar
et al (1998) to indirectly estimate hazard ratios from Cox
regression analyses and P values from log-rank tests, enabling us
to incorporate a large number of studies in our meta-analyses.
Moreover, we performed an in-depth analysis of study quality, the
presence of publication bias and the extent and sources of
heterogeneity between published studies.
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Search strategy and selection criteria
A MEDLINE, PubMed and EMBASE search for studies investigat-
ing the prognostic significance of p53, EGFR and HER-2/neu in
ovarian cancer was performed. Studies published between 1990
and January 1st, 2009, were examined. MESH words used were
‘ovarian neoplasm’, ‘receptor epidermal growth factor’, ‘receptor
erbB-2’ and ‘protein p53’. Additional words used for title search
were marker* or prognost* or survival. The references of all
publications and reviews were hand-searched to identify missing
relevant publications.
Studies were included in the meta-analysis if they met the
following criteria: (1) patients included had chemonaive epithelial
ovarian cancer; (2) the endpoint investigated was disease specific
or overall survival; (3) the study reported a hazard ratio (HR) and
standard error (s.e.) or data sufficient to estimate the HR and s.e.
from univariate survival analysis. Where a single study was
reported on multiple occasions, only the report with the largest
patient group or the most complete data was included. If a study
reported results for more than one method (i.e., immunohisto-
chemistry (IHC) and mutational analysis), for more than one well-
described patient group or for multiple antibodies, results of all
analyses were included in the meta-analysis. Thirteen studies
published in languages other than English or German were
excluded from the meta-analysis (for an overview, see Supple-
mentary Table 1). Reviews, non-original articles and studies on
non-epithelial or borderline ovarian tumours were also excluded.
Two researchers (PdG and APGC) independently examined
abstracts of articles (n¼614) to decide whether full-text articles
should be obtained (Figure 1). Cases of disagreement were
resolved by discussing the title and abstract. Full-text articles
(n¼216) were examined and excluded if a more detailed
examination revealed that they did not meet the inclusion criteria.
The sample size of included studies did not differ from the sample
size of excluded studies (data not shown). Where applicable, we
adhered to the QUORUM criteria for improving the quality of
reporting of meta-analyses (Moher et al, 1999).
Data extraction
Data were extracted independently by two investigators (PdG and
APGC) by means of a predefined form. Topics in this form were
year of publication, country, number of patients, years of patient
inclusion, method of case selection (retrospective or prospective
cohort of patients), age at time of diagnosis (mean, median, range),
distribution of stage, tumour type and differentiation grade,
treatment, amount of residual tumour after primary surgery,
response to chemotherapy, time of follow-up (median, mean,
minimum and maximum), assay method and scoring protocol
used, number of marker positive and negative tumours, numbers
of (disease specific and overall) death, and results of univariate
survival analyses.
Assessment of study quality and publication bias
Study quality was assessed independently by two investigators
(PdG and APGC) by means of a predefined form. As there are no
generally accepted standards for measuring study quality, this
form was derived from the work of McShane et al (2005) and
Hayes et al (1996) (Supplementary Table 2). In summary, the
following criteria were investigated: whether (1) the study reported
inclusion and exclusion criteria; (2) study data were prospectively
or retrospectively gathered; (3) patient and tumour characteristics
were sufficiently described; (4) the assay used to measure
biomarker expression was sufficiently described; (5) a definition
of the study endpoint was provided; (6) the follow-up time of
patients in the study was described; (7) the study reported how
many patients were lost to follow-up or were not available for
statistical analysis. Studies with a total score of 8 were considered
to show the highest study quality, whereas a zero score indicated
the lowest quality.
Additionally, studies were scored as phase I–III prognostic
marker studies according to the classification proposed by Simon
and Altman (1994). Early exploratory studies are designated phase
I studies, whereas phase II studies investigate the association of a
biomarker with patient prognosis and are hypothesis generating in
nature, and phase III studies are large confirmatory studies of
prestated hypotheses.
Publication and selection bias were investigated through a
funnel plot (Egger et al, 1997).
Statistical analysis
Statistical analyses were carried out using SPSS version 12.01
(SPSS, Chicago, IL, USA), Review Manager version 4.2 (The
Cochrane Collaboration, the Nordic Cochrane Centre, Copenhagen,
Denmark) and MLWIN version 2.0 (Centre for Multilevel
Modelling, University of Bristol, Bristol, UK).
The first goal of our meta-analysis was to obtain a log-hazard
ratio and its standard error for each study according to methods
previously described by Parmar et al (1998). If the study reported
results of a univariate Cox regression analysis, log-hazard and its
standard error were directly included in the meta-analysis. When
the study did not report the standard error, it was estimated from
the 95% confidence interval (CI) or P value of univariate Cox
regression analyses. If results of univariate Cox regression analyses
were not presented in the paper, the log-hazard ratio and its
standard error were estimated indirectly from P values of the log-
rank test. Subsequently we performed a meta-analysis using the
DerSimonian–Laird random effects model (DerSimonian and
Laird, 1986), applying the inverse of variance as a weighing factor.
Heterogeneity was investigated by use of the I
2 statistic, which
takes values from 0 to 100% (Higgins and Thompson, 2002). An
I
2 value 450% was considered to represent substantial hetero-
geneity between studies.
Quantitative assessment of sources of heterogeneity was under-
taken by meta-regression analysis (Thompson and Higgins, 2002).
The following potential sources of heterogeneity were explored:
study quality score, year of publication (o or 4 median year of
publication), data collection (prospective or retrospective), region
(Europe, United States, Asia or other), FIGO stage (o or 450%
FIGO stage III/IV tumours), tumour type (o50% or 450% serous
tumours), differentiation grade (o50% or 450% grade III or
undifferentiated tumours), type of tumour tissue (frozen or
paraffin-embedded), assay method (IHC or other), primary
antibody (monoclonal or polyclonal), cut-off value for positive
Literature search : examination of abstracts (n = 1263)
Examination of full-text articles (n = 282)
Hand-search references to identify relevant missing publications
P53
EGFR
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Figure 1 Search strategy.
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smarker expression (o or 4 median percentage of positive
tumours) and percentage of positive tumours (o or 4 number of
percentage positive tumours). For each potential source of
heterogeneity, a multilevel model was developed with the logHR
as dependent variable and the sources of heterogeneity as
independent variables.
RESULTS
Study characteristics
For p53, 62 studies reporting results of 75 analyses in 9448 patients
were included (Supplementary Table 3; median study size 102
patients, range 20–783; Hartmann et al, 1994; Klemi et al,1 9 9 5 ;
Allan et al, 1996; Eltabbakh et al, 1997; Viale et al, 1997; Darai et al,
1998; Marx et al, 1998; Silvestrini et al, 1998; Anttila et al,1 9 9 9 ;
Baekelandt et al, 1999; Kassim et al, 1999; Wen et al, 1999; Blegen
et al, 2000; Laframboise et al, 2000; Levesque et al, 2000; Ozalp et al,
2000; Schildkraut et al, 2000; Shahin et al, 2000; Birner et al,2 0 0 1 ;
Howells et al, 2001; Reles et al, 2001; Saegusa et al, 2001; Schuyer
et al, 2001; Skirnisdottir et al, 2001a; Berker et al, 2002; Hawes et al,
2002; Pieretti et al, 2002; Sagarra et al, 2002; Havrilesky et al,2 0 0 3 ;
Ikeda et al, 2003; Konstantinidou et al, 2003; Nakayama et al,2 0 0 3 ;
Tachibana et al, 2003; Wisman et al,2 0 0 3 ;B a l iet al, 2004; Ceccaroni
et al, 2004; Iba et al, 2004; Nielsen et al, 2004; Seo et al, 2004; Concin
et al, 2005; Goodheart et al, 2005; Kaern et al, 2005; Kaiser et al,2 0 0 5 ;
Terauchi et al, 2005; Green et al, 2006; Lee et al, 2006; Ueno et al,
2006; Yakirevich et al, 2006; de Graeff et al, 2006; Brustmann, 2007;
Galic et al, 2007; Malamou-Mitsi et al, 2007; Materna et al,2 0 0 7 ;
Psyrri et al, 2007; Bartel et al, 2008; Darcy et al, 2008; Garcia-Velasco
et al, 2008; Giordano et al, 2008; Kobel et al, 2008; Leffers et al,2 0 0 8 ;
Tomsova et al, 2008; Vartiainen et al, 2008). There were 13
prospective studies and 49 retrospective studies. All studies were
designated phase II biomarker studies. No phase III biomarker
studies were found, although two large studies fulfilled almost all
requirements (de Graeff et al, 2006; Darcy et al, 2008). Most studies
used IHC (n¼60) or mutational analysis (single-strand conforma-
tion polymorphism analysis and/or sequencing, n¼11) to determine
p53 status. Other methods included fluorescence in situ hybridisa-
tion (FISH, n¼1) and immunoassays (n¼2). For IHC staining, the
most frequently used antibodies were DO1 (n¼10) and DO7
(n¼32). Six studies did not specify the antibody used. Cut-off values
for positive immunostaining varied widely, ranging from 45% to
490% nuclear staining. The median percentage of p53 positive
tumours was 50% (range 13.7–82.0%). A significant association of
p53 expression with overall survival in univariate analysis was
reported in 29 (38.6%) analyses, of which 25 reported an association
with poor survival and 4 an association with improved survival.
For EGFR, 15 studies in 2471 patients were included in the meta-
analysis (Supplementary Table 4; median study size 106 patients,
range 40–783; Kaufmann et al, 1995; Scambia et al, 1995; Bartlett
et al, 1996; Fischer-Colbrie et al, 1997; Skirnisdottir et al, 2001b;
Elie et al, 2004; Nielsen et al, 2004; Psyrri et al, 2005; Raspollini
et al, 2005; Schilder et al, 2005; Wang et al, 2005; Castellvi et al,
2006; Lassus et al, 2006; Brustmann, 2008; de Graeff et al, 2008).
Again, all studies were classified as phase II biomarker studies.
Three studies prospectively collected data. Eleven studies per-
formed IHC staining for determination of EGFR expression using
five different antibodies and six cut-off values for positive EGFR
expression. Other methods included
125EGF binding assay (n¼3)
and RT–PCR (n¼1). Positive immunostaining was observed in
6.2–72.6% (median 35%) of tumours, and in 7 studies (63.6%)
EGFR expression predicted poor overall survival.
For HER-2/neu, 20 studies reporting results of 21 analyses in
3055 patients were subjected to final analysis (Supplementary
Table 4; median study size 111 patients, range 40–783; Berchuck
et al, 1990; Fajac et al, 1995; Kaufmann et al, 1995; Medl et al, 1995;
Wang et al, 1999, 2005; Davidson et al, 2000; Skirnisdottir et al,
2001b; Camilleri-Broet et al, 2004; Nielsen et al, 2004; Verri et al,
2005; Castellvi et al, 2006; Surowiak et al, 2006; Malamou-Mitsi
et al, 2007; Pils et al, 2007; Steffensen et al, 2007; Tuefferd et al,
2007; de Graeff et al, 2008; Garcia-Velasco et al, 2008; Tomsova
et al, 2008). All studies were designated phase II biomarker studies.
Two studies prospectively collected patient data. Methods to
determine HER-2/neu status included IHC (n¼16) with 3 studies
additionally performing FISH for ambiguous cases, PCR (n¼1),
FISH only (n¼1), Southern blot (n¼1) and HER-2/neu im-
munoassay (n¼1). Antibodies used for IHC staining included
CB11 (n¼3), TA1 (n¼1), MCO102 (n¼1), NCL-CBE-356 (n¼1),
the Herceptest kit (n¼4) and unspecified antibodies (n¼3). Five
different cut-off values for positive HER-2/neu protein expression
were used. The median percentage of positive tumours was 18.0%
(range 5–57%). Eight studies (40%) reported that HER-2/neu was
a significant predictor of overall survival in univariate analysis, of
which one study reported an association between HER-2/neu
staining and improved survival.
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Figure 2 Funnel plots. Funnel plots showing the relationship between
the effect size of individual studies (hazard ratios for overall survival,
horizontal axis) and the precision of the study estimate (standard error,
vertical axis) for p53, EGFR and HER-2/neu.
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The median quality score was 5 (range 1–8) for p53, 5 for EGFR
(range 3–7) and 5 for HER-2/neu (range 3–8; Supplementary
Tables 3–5). High study quality was related to a high journal
impact factor for p53 (P¼0.010), but not for EGFR (P¼0.59) and
HER-2/neu (P¼0.65).
Investigation of bias by a funnel plot showed substantial funnel
plot asymmetry for HER-2/neu and EGFR, suggesting the presence
of publication and/or selection bias (Figure 2). For p53, no funnel
plot asymmetry was found.
Meta-analysis and assessment of heterogeneity
P53 Meta-analysis of 53 studies on the prognostic value of p53
expression showed that aberrant of p53 status is associated with poor
overall survival (HR obtained from DerSimonian–Laird random
effects model: 1.55 (95% CI 1.40–1.71); Figure 3), although there was
heterogeneity between studies (I
2¼44.4%). Subgroup analysis
revealed a prognostic impact for IHC studies, IHC studies with the
DO7 antibody, studies using mutational analysis and studies with a
quality score 46. However, considerable heterogeneity remained
present, indicating that not all sources of heterogeneity could be
accounted for (Table 1). When the meta-analysis was restricted to
studies reporting results of (subgroup) analyses for serous tumours
(Bali et al, 2004; Terauchi et al,2 0 0 5 ;U e n oet al, 2006; Yakirevich
et al, 2006; Kobel et al, 2008; Vartiainen et al, 2008) p53 status was
also a predictor of poor survival. Unfortunately, the number of
studies reporting results for the other histological subtypes was too
small to perform a pooled analysis. Meta-regression analysis revealed
that the outcome of analysis was influenced by FIGO stage
distribution. When results of six studies reporting results for stage
III/IV tumours were subsequently pooled, p53 status was no longer
of prognostic value (Table 1).
EGFR Results of meta-analysis for EGFR showed a significant
relationship between overexpression of EGFR and poor patient
outcome (HR: 1.65 (95% CI 1.25–2.19); Figure 4). Although
significant heterogeneity was present (I
2¼74.3%), the sources of
heterogeneity could not be determined in meta-regression analysis.
Restricting the analysis to studies that used IHC staining for
determination of marker expression did not alter results of
heterogeneity tests (Table 1). However, further analysis showed
that heterogeneity was partly due to results of the study by Psyrri
et al (2005). When this study was excluded from the meta-analysis,
less heterogeneity was observed.
HER-2/neu Meta-analysis of univariate analyses on the progno-
stic value of HER-2/neu showed that overexpression of HER-2/neu
is associated with poor overall survival (HR: 1.67 (95% CI
1.34–2.08); Figure 5), but again considerable heterogeneity was
present (I
2¼59.6%). Of note, none of the studies using immuno-
histochemical staining followed by FISH for ambiguous
samples reported a statistically significant relationship between
HER-2/neu expression and survival (Castellvi et al, 2006;
Malamou-Mitsi et al, 2007; Tuefferd et al, 2007). The most
important factor explaining the lack of homogeneity between
studies was study quality, with studies of low quality reporting
more significant results.
DISCUSSION
In this study, we present a pooled estimate of the prognostic value
of p53, EGFR and HER-2/neu in epithelial ovarian cancer. Our
results show that as single markers, p53, EGFR and HER-2/neu are
not likely to be useful as prognostic factors in clinical practice
(pooled HR for all included studies: 1.47 (95% CI 1.33–1.61)
for p53; 1.65 (95% CI 1.25–2.19) for EGFR and 1.67 (95% CI
1.34–2.08) for HER-2/neu). Furthermore, our study clearly
indicates that adequate conduct and complete reporting are
imperative for improving the quality of prognostic factor studies
in ovarian cancer.
Although protein expression of p53 and EGFR as assessed by
IHC staining has a modest effect on prognosis, neither p53 nor
EGFR immunostaining predicts clinical outcome in a manner
comparable to well-known clinicopathological prognostic factors
such as tumour stage and residual tumour after primary surgery.
Our results also show that p53 mutations have prognostic value
in epithelial ovarian cancer, although this was of borderline
significance. However, this analysis was affected by small
sample size and methodological issues, such as the use of
different techniques for mutational analyses and the analysis of
different exons.
For HER-2/neu and EGFR, the ability to draw reliable
conclusions from meta-analysis was affected by the presence of
considerable publication bias for studies with a small sample size
yielding non-significant results. The presented hazard ratios
might, therefore, be an overestimation of the true effect size.
More importantly, meta-regression analysis demonstrated that
studies that are poorly designed or reported produce higher
estimates of the prognostic value of HER-2/neu. This finding has
previously been demonstrated in a meta-analysis of clinical trials,
where incorporation of results of poor quality randomised
controlled trials contributed to significant exaggeration of
treatment efficacy (Moher et al, 1998).
It has long been appreciated that the histological subtypes of
ovarian cancer show considerable differences with respect to stage
at diagnosis, response to chemotherapy and underlying molecular
abnormalities (Bell, 2005). This was recently demonstrated by
Kobel et al (2008), who assessed the expression of 21 candidate
biomarkers in a large cohort of 500 ovarian carcinomas and
subsequently performed subgroup analyses for the different
histological subtypes. Their results showed that the expression as
well as the prognostic value of most biomarkers considerably
varied between the subtypes. In this study, we assessed the
prognostic value of p53 in six studies presenting (subgroup)
analyses for p53 in serous tumours. The results of this analysis did
not show a large difference between the prognostic value of p53 in
serous tumours and it prognostic value in the entire cohort.
Additionally, we performed a subgroup analysis for four studies
reporting six analyses on the prognostic value of p53 in stage III/IV
tumours. In this group, p53 was not of prognostic value. However,
the number of studies that could be analysed was small and we
were not able to perform a pooled analysis for the other
histological subtypes. Our results underscore the importance of
biomarker analysis in homogeneous subgroups of patients, such as
patients with a particular disease stage, tumour type or
differentiation grade. To perform these kinds of analyses,
international collaboration is critical. Furthermore, the submission
Figure 3 Forest plot showing results of studies on the prognostic value of p53 expression. Hazard ratios and 95% CI (confidence interval) of individual
studies for patients with p53 positive tumours. Hazard ratios: squares whose heights are inversely proportional to the standard error of the estimate, and
their respective confidence intervals (horizontal lines). Summary hazard ratio: diamond with horizontal limits at the confidence limits and width inversely
related to its standard error. Hazard ratios higher than 1 indicate an increased risk of death for patients with a tumour with aberrant p53 status.
Abbreviations: MUT¼results of mutation analysis; IHC¼results of immunohistochemical staining; cyt¼results for cytoplasmic immunostaining;
nucl¼results for nuclear immunostaining; P arm¼results for patients treated with cisplatin; PC arm¼results for patients treated with cisplatin/
cyclophosphamide.
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sStudy HR (95% CI)
Allan
Anttilla
Baekelandt
Bali
Bartel (IHC)
Bartel (MUT)
Berker
Birner
Blegen
Brustmann
Ceccaroni
Concin
Darai
de Graeff
Eltabbakh
Galic
Garcia-Velasco
Giordano
Goodheart IHC
Goodheart MUT
Green
Hawes
Howells
Iba
Ikeda
Kaern
Kaiser
Kassim
Klemi
Lee
Marx
Materna
Nakayama
Nielsen
Ozalp FISH
Ozalp IHC
Pieretti IHC
Pieretti MUT
Psyrri (cyt)
Psyrri (nuc)
Reles IHC
Reles MUT
Saegusa
Sagarra
Schildkraut
Schuyer IHC
Schuyer MUT
Seo
Shahin
Silvestrini P arm
Silvestrini PC arm
Skirnisdottir
Tachibana BP53-12
Tachibana DO1
Tachibana DO7
Terauchi
Tomsova
Ueno
Vartianinen
Viale
Wen
Wisman
Yakirevich
Leffers
Levesque
Malamou-Mitsi
Kobel
Konstantinidou
Laframboise
Hartmann
Havrilevsky IHC >0%
Havrilevsky IHC >30%
Havrilevsky MUT
Darcy (GOG111)
Darcy (GOG157)
1.72  [0.92,   3.21]
1.92  [1.43,   2.57]
1.65  [1.20,   2.26]
1.65  [1.20,   2.26]
2.01  [1.12,   3.63]
1.05  [0.60,   1.86]
3.74  [1.07,   13.12]
1.67  [0.91,   3.06]
1.34  [0.54,   3.29]
1.60  [0.66,   3.87]
1.79  [0.74,   4.31]
2.34  [1.38,   3.97]
2.83  [1.04,   7.69]
1.86  [0.95,   3.62]
1.13  [0.78,   1.64]
1.35  [1.03,   1.78]
1.46  [1.01,   2.12]
0.76  [0.50,   1.17]
0.64  [0.19,   2.11]
3.71  [1.53,   8.95]
1.00  [0.28,   3.58]
0.99  [0.21,   4.66]
0.96  [0.68,   1.37]
1.38  [1.03,   1.85]
1.30  [0.79,   2.12]
1.40  [0.91,   2.16]
0.30  [0.11,   0.85]
2.72  [1.32,   5.61]
1.28  [0.67,   2.45]
1.77  [1.00,   3.12]
0.60  [0.29,   1.24]
2.20  [0.49,   9.97]
0.47  [0.23,   0.97]
3.19  [1.02,   9.94]
1.82  [1.26,   2.64]
1.40  [0.99,   2.00]
1.80  [0.78,   4.19]
0.93  [0.49,   1.78]
1.88  [0.93,   3.80]
1.46  [1.09,   1.96]
2.75  [1.41,   5.35]
0.76  [0.44,   1.32]
2.75  [1.72,   4.39]
2.86  [0.95,   8.56]
2.92  [1.41,   6.02]
1.31  [1.12,   1.53]
1.31  [0.40,   4.25]
4.48  [1.56,   12.91]
1.34  [0.79,   2.27]
1.31  [0.77,   2.22]
0.42  [0.24,   0.74]
0.36  [0.21,   0.62]
1.45  [0.98,   2.14]
1.58  [1.09,   2.30]
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allow for analysis of specific subgroups although maintaining
prognostic power.
Most studies in the meta-analysis used IHC staining to study
expressions of p53, EGFR and HER-2/neu. Although IHC staining
is simple and cost-effective to perform, results are highly
dependent on a variety of methodological factors such as storage
time and fixation method of paraffin-embedded tissues, choice of
primary antibody and IHC staining protocol (Jacquemier et al,
1994; Hall et al, 2004). In this study, differences in IHC staining
protocols and cut-off values for positive protein expression
ranging from 45t o490% positively stained cells may have
contributed to the observed heterogeneity. Our results, therefore,
make a strong case for international consensus on staining and
scoring protocols.
As a first step towards quality assessment of prognostic
factor studies to be included in meta-analyses, we have developed
a quality score. For meta-analyses evaluating results of both
clinical trials and diagnostic studies, such criteria are available
and are widely used to either exclude studies low-quality studies
or evaluate study quality (Jadad et al, 1996; Whiting et al, 2003).
As our quality score was newly developed for this study and
was not extensively validated, we chose not to exclude studies
from statistical analysis beforehand because of a low score. Based
on results of meta-regression analysis we do, however, believe that
it provides a good estimation of study quality. In future studies,
our quality score might serve as a further step towards the
development of evidence-based quality assessment tools for meta-
analyses of prognostic factor studies. In addition, the use of the
recently published REMARK guidelines for reporting of prognostic
factor studies will aid in a more complete and transparent
reporting (McShane et al, 2005), thereby also increasing
the number of high-quality studies that can be included in a
meta-analysis.
Table 1 Summarized hazard ratios
Analysis N Pooled HR (95% CI)
a I
2 value (%) P-value*
P53
All studies 75 1.47 (1.33–1.61) 58.9 o0.001
Studies using IHC staining 41 1.47 (1.33–1.64) 59.8 o0.001
Studies using IHC staining with the DO7 antibody 32 1.49 (1.26–1.75) 69.0 o0.001
Studies using mutational analysis 11 1.33 (1.03–1.70) 47.7 0.03
Studies with a quality score X5
b 40 1.44 (1.27–1.63) 66.4 o0.001
Studies restricted to serous tumours
c 6 1.61 (1.09–2.38) 61.3 0.02
Studies restricted to stage III/IV tumours 8 0.91 (0.59–1.39) 71.8 o0.001
HER-2/neu
All studies 21 1.67 (1.34–2.08) 59.8 o0.001
Studies using IHC staining 13 1.78 (1.28–2.46) 73.0 o0.001
Studies with a quality score X5
b 12 1.46 (1.13–1.89) 57.0 0.008
EGFR
All studies 15 1.65 (1.25–2.19) 74.3 o0.001
Studies using IHC staining 11 1.50 (1.08–2.09) 76.6 o0.001
All studies except Psyrri et al (2005) 14 1.47 (1.17–1.84) 59.5 0.002
HR¼hazard ratio; 95% CI¼95% confidence interval; IHC¼immunohistochemical staining.
aPooled hazards ratios were obtained from using a DerSimonian–Laird random
effects model, applying the inverse of variance as a weighing factor.
bCut-off values for quality scores were based on the median quality score of included studies for a specific
marker.
cFour studies restricted to serous tumours and two studies (Ueno et al, 2006; Kobel et al, 2008) reporting results of subgroup analysis for serous tumours. *P values
obtained from w
2-test for heterogeneity.
Study HR (95% CI)
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Figure 4 Forest plot showing results of studies on the prognostic value of EGFR expression. Hazard ratios and 95% confidence intervals for patients with
EGFR positive tumours (symbols as in Figure 3).
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sWe have also designated all studies phase I–III prognostic
factor studies according to a classification proposed by Simon and
Altman (1994). Although several large studies on the prognostic
value of p53 and HER-2/neu have been performed, no studies met
the stringent criteria for phase III biomarker studies.
A prespecified hypothesis, the description of eligibility criteria
and a sufficiently large number of patients were often lacking. In
addition, almost none of the studies were specifically designed to
determine the prognostic impact of p53, EGFR or HER-2/neu as
single markers. These results underscore the need for well-
designed studies with clearly stated hypotheses that examine the
relationship between biomarker expression and clinical outcome.
Although this study shows that p53, EGFR and HER-2/neu
immunostaining do not have a strong direct relationship with
survival, it is more than likely that their respective pathways do
influence patient prognosis. In future studies, several approaches
could be taken to elucidate the prognostic value of these pathways.
For instance, IHC staining of activated (phosphorylated) receptors
and key regulatory proteins involved in upstream and downstream
signalling may be more informative than immunostaining of single
markers regardless of their activation status (Wang et al, 2005;
de Graeff et al, 2008). In addition, other methods to assess pathway
activation status may be employed to identify prognostic factors.
For instance, EGFR amplification as determined by FISH has been
shown to be independently associated with poor survival in vulvar
cancer and in head and neck squamous cell carcinomas (Chung
et al, 2006; Growdon et al, 2008). Two recent reports in ovarian
cancer also suggest that increased gene copy number of EGFR is
more strongly related to survival than protein expression (Lassus
et al, 2004, 2006).
Other attractive approaches for the identification of novel
prognostic and predictive factors include the identification of
genes and pathways by microarray analysis. Traditional prognostic
factor studies, including those on p53, HER-2/neu and EGFR, have
until now mainly focused on the prognostic value of single genes.
Over the past years, it has become apparent that this ‘one gene, one
outcome’ hypothesis is an oversimplification of the multiple
genetic and epigenetic mechanisms that account for ovarian cancer
survival. Using pathway analysis of large datasets such as
microarray data (Bild et al, 2006), alterations in the p53, EGFR
and HER-2/neu pathways rather than single genes can be analysed.
Ultimately, the identification or deregulated pathways in a single
tumour may lead to a more precise estimation of patient prognosis
and might also reveal novel therapeutic targets. However, these
studies often need a far more complex design and statistical
analysis compared to single marker studies. It is, therefore,
especially important to address methodological issues when
designing and reporting these analyses, and to take possible
sources of heterogeneity into account.
There are some limitations to this meta-analysis. Firstly,
especially for EGFR and HER-2/neu considerable heterogeneity
was observed. When subgroup analyses for more homogeneous
groups of studies was performed, for example, only studies
performing IHC staining, heterogeneity remained present. This
indicates that not all sources of heterogeneity could be accounted
for in this meta-analysis, and that results should be interpreted
with caution. Secondly, we have restricted our analysis to
published studies written in English or German. Thirteen, mostly
small studies that met eligibility criteria according to the abstracts
were excluded based on language criteria. This may result in
publication or language bias leading to an overestimation of effect
sizes (Egger et al, 1997; Pham et al, 2005). Although this was not
the case for p53, there was clear evidence of publication bias for
EGFR and HER-2/neu. Thirdly, our meta-analysis is based on
unadjusted estimates, whereas a more precise estimate could be
obtained using a multivariate analysis adjusting for clinicopatho-
logical variables. However, multivariate analyses reported in the
included studies used various models and different covariates, and
could, therefore, not be combined into a pooled estimate.
In conclusion, our study shows that although aberrations of p53
and EGFR have a modest effect on survival in ovarian cancer, they
are currently unlikely to influence clinical decision-making.
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Figure 5 Forest plot showing results of studies on the prognostic value of HER-2/neu expression. Hazard ratios and 95% CI (confidence intervals) for
patients with HER-2/neu positive tumours (symbols as in Figure 3).
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sIdentification of multiple methodological flaws and sources of
heterogeneity in currently available prognostic factor studies
should contribute to improve design and reporting of future
prognostic and predictive factor studies. Hopefully, this way,
deregulated molecular biological factors/pathways will be identi-
fied that will make a difference in clinical decision making,
ultimately resulting in effective, individualised targeted therapy for
ovarian cancer patients.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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